Santhera price target lowered to CHF 25 from CHF 30 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Santhera Pharmaceuticals to CHF 25 from CHF 30 and keeps a Buy rating on the shares. The company completed multiple transactions completed, providing an operational runway through to potential cash flow breakeven, the analyst tells investors in a research note.